肝动脉化疗栓塞联合索拉非尼治疗中晚期肝细胞癌的临床分析

目的 通过对经导管肝动脉化疗栓塞(TACE)联合索拉非尼治疗中晚期肝细胞癌患者的疾病进展时间(TTP)或总生存期(OS)的分析,观察介入栓塞与抗血管生成相结合治疗中晚期肝细胞癌的疗效;并分析治疗的安全性,为中晚期肝细胞癌的标准治疗模式提供证据来源.方法 收集广东省人民医院肿瘤中心2007年4月至2010年1月经病理证实或临床确诊的符合标准的中晚期肝细胞癌患者36例,其中男33例、女3例;行TACE治疗后3～7 d内连续口服索拉非尼(商品名:多吉美)(每片200 mg),每次2片,每天2次.每4～8周为一个疗程,根据RECIST标准进行疗效评价,主要观察患者的肿瘤进展时间(TTP)及总生存期(OS),并记录不良事件.所有生存率采用寿命表法,所有生存率曲线均采用Kaplan-Meier法.结果 随访至2010年3月,可评价的36例患者中,死亡14例,存活22例,中位肿瘤进展时间(mTTP)为8.62个月(95%CI:6.51～10.24个月),中位生存期(mOS)为12.41个月(95%CI:9.57～14.80个月).36例患者中,存活的22例,观察时间内的患者总体存活率为61.1%.存活病例中,没有CR病例,1例PR,15例SD,6例PD;疾病控制率(DCR)(CR+PR+SD)为44.4%.服用索拉非尼主要不良反应为手足皮肤反应、腹泻、乏力及食欲下降,经对症处理后绝大多数可以明显缓解.结论 TACE联合索拉非尼治疗中晚期肝细胞癌患者有可能获得较长的生存时间和疾病稳定状态,进一步丰富了中晚期肝细胞癌的治疗模式.口服索拉非尼的不良反应可以耐受.

Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma

Objective To provide more evidence sources to the standard treatment for patients with advanced hepatocellular carcinoma,the writer analyze patients' time to progression (TTP) and overall survival (OS) after patients receiving transcatheter arterial chemoembolization (TACE) combined with sorafenib as a treatment of advanced hepatocellular carcinoma (HCC);observe the healing effect embolization combined with anti-angiogenic treatment for advanced hepatocellular carcinoma;and also analyze treatment of security.MethodsThere are 36 patients,33 male and 3 female had been Pathologically or clinical diagnosis.After receiving Transcatheter Arterial Chemoembolization (TACE)therapy,in the following 3 to 7 days,this group of patients continuously take sorafenib ( brand name:Nexavar) ( per tablet 200 mg),2 tablets each time,2 times a day.Every 4 to 8 weeks is called as one period of treatment.Referring to RECIST Evaluation,the writers mainly observe patients' tumor progression (TTP) and overall survival (OS),record adverse events.Using life table method to analyze survival rate,using Kaplan-Meier method to analyze all the survival curves.Results Till March,2010,14 of 36evaluable patients died and 22 survive;the median time to tumor progression (mTTP) to 8.62 months (95%CI:6.51-10.24 months);the median survival time (mOS) of 12.41 months (95% CI:9.57-14.80months).The overall survival rate to observation period is 61.1%;36 patients had been studied,22survive.Among the survivals,there is no CR cases,and 1 case PR,15 patients SD,6 patients PD;disease control rate (DCR) (CR + PR + SD) is 44.4%.The side effects of taking Sorafenib mainly are hand-foot skin reaction,diarrhea,fatigue and loss of appetite.These side effects can be markedly eased after symptomatic treatment.Conclusion Combined with sorafenib treatment may give patients with advanced hepatocellular carcinoma a longer longevity and keep the disease in a steady state.This therapy can be added into the treatments to patients with advanced hepatocellular carcinoma.The side effects of taking Sorafenib (Nexavar) could be stand.